

Date: 1st June, 2020

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai - 400 001

Dear Sir/Madam

Sub: Annual Disclosure under SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated 26th November, 2018 on Fund raising by issuance of Debt Securities by Large Entities ('SEBI Circular')

With reference to the captioned subject and para 4.1.ii. of the SEBI Circular, please find enclosed herewith Annual Disclosure w.r.t. the details of the incremental borrowings during the financial year 2019-20.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited

Charandeep Singh Saluja Company Secretary

Encl.: A/a



Annual Disclosure

- 1. Name of the Company: Alembic Pharmaceuticals Limited
- 2. CIN: L24230GJ2010PLC061123
- 3. Report filed for FY: 2019-20
- 4. Details of the borrowings (in Rs. cr.)

Sr.	Particulars	Details
No.		Dotails
i.	Incremental borrowing done in FY (a)	200.00
ii.	Mandatory borrowing to be done through issuance of debt securities (b) = (25% of a)	50.00
iii.	Actual borrowings done through debt securities in FY (c)	Nil
iv.	Shortfall in the mandatory borrowing through debt securities, if any (d) = (b) - (c)	50.00
	{If the calculated value is zero or negative, write "nil"}	
V.	Reasons for short fall, if any, in mandatory borrowings through debt securities	The amount required to be borrowed by the Company through debt securities (as mentioned above at 4 ii.) is not significant considering the overall borrowing of the Company. Issue of debt securities for such an amount is administratively expensive and carries higher cost of funds as compared to other long-term instruments. Hence, the Company did not borrow the said amount.

For Alembic Pharmaceuticals Limited

Charandeep Singh Saluja Company Secretary

0265 - 3007284

Date: 1st June, 2020

R. K. Baheti

Director - Finance & CFO

0265 - 3007973